The Vaccines Against Infectious Diseases (VID) Study Section reviews applications concerned with vaccine development against all classes of pathogens (except HIV). A defining feature of applications reviewed in this study section is the measurement of vaccine efficacy or vaccine-induced immune responses. This study section also reviews applications focusing on the efficacy, improvement, and safety of vaccines already approved for human or veterinary use. Applications often involve animal models, human samples, or human subjects. Applications that emphasize foundational vaccine research, such as antigen identification or technological advancements of vaccine platforms or adjuvants, are generally reviewed in the relevant pathogen, immunology, or technology-focused study section.
The membership panel is a list of chartered members only.
- Vaccines against pathogens of clinical or veterinary interest, including bacteria, viruses (except HIV), parasites, fungi, bacterial toxins, and pathogenic agents that have biodefense implications
- Pre-clinical and clinical vaccine testing, including protection from disease, immune response characterizations, toxicology, and safety studies
- Vaccine formulation and production for all classes of vaccines (inactivated vaccines, live-attenuated vaccines, mRNA vaccines, toxoid vaccines, viral vector vaccines, and subunit, recombinant, polysaccharide, and conjugate vaccines).
- Adjuvant, platform, and delivery optimization
- Existing vaccine performance, utility, and safety, including population-level studies of vaccine efficacy, limitations, and side effects
Shared Interests and Overlaps
There are shared interests in vaccine development with pathogen-focused study sections, including Bacterial Host Interactions (BHI), Pathogenic Eukaryotes (PTHE), and Viral Pathogenesis and Immunity (VPI). Applications that emphasize earlier stages of vaccine development, such as the identification and initial characterization of protective pathogenic antigens, their cloning and development of vector systems, and the development and immunologic evaluation of the adjuvant systems, may be reviewed in the relevant pathogen-focused study section. Applications that emphasize measurement of vaccine efficacy or vaccine-induced immune responses as the endpoint may be reviewed in VID.
There are shared interests in infection control strategies with Transmission of Vector-Borne and Zoonotic Diseases (TVZ). Applications that emphasize strategies that disrupt the pathogen’s complex life cycle, such as manipulation of the pathogen, host, or environment may be reviewed in TVZ. Applications that emphasize vaccine design and efficacy may be reviewed in VID.
There are shared interests in immune responses to pathogens with Immunity and Host Defense (IHD). Applications that emphasize basic immunological studies, such as mechanistic studies of the innate, systemic, and mucosal immune responses to microbial organisms may be reviewed by IHD. Applications that emphasize generation or testing of vaccines or immune responses to vaccines may be reviewed in VID.
There are shared interests in immune mechanisms and responses with Cellular and Molecular Immunology A (CMIA). Applications that emphasize antibody structure, function, engineering, or biochemistry in all other contexts may be reviewed in CMIA. Applications focused on immune responses to vaccines may be reviewed in VID.
There are shared interests in immune mechanisms and responses with Cellular and Molecular Immunology B (CMIB). Applications that emphasize mechanisms of basic immunobiology and memory T and B cell development may be reviewed in CMIB. Applications focused on immune responses to vaccines may be reviewed in VID.
There are shared interests in immune response characterization with Innate Immunity and Inflammation (III). Applications that emphasize mechanisms of innate immunity and inflammation, including in response to pathogen infections, may be reviewed in III. Applications that emphasize innate immunity in the context of vaccine responses may be reviewed in VID.
There are shared interests with Innovations in Nanosystems and Nanotechnology (INN) in developing novel vaccine nanomaterials. Applications that emphasize the design, synthesis, and development of nanomaterials may be reviewed in INN. Applications that emphasize the use of existing nanomaterials in a vaccine or on testing the efficacy of a vaccine-related nanomaterial may be reviewed in VID.
There are shared interests in nucleic acid-based vaccine development with Drug and Biologic Therapeutic Delivery (DBTD) and Nucleic Acid Therapeutic Delivery [BBBT (81)]. Applications that emphasize novel methods for vaccine delivery, with a focus on bioengineering principles, may be reviewed in DBTD or BBBT (81). Applications that emphasize vaccine testing, efficacy, and immune responses may be reviewed in VID.